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, platelets 438,000/mm 3 . Peripheral blood smear showed promyelomonocytes, myelocytes and the characteristic "bone marrow appearance". Philadelphia chromosome was positive and WBC alkaline phosphatase was nearly zero. The patient was started on treatment with imatinib and is currently been followed up in a stable condition. This is the first case of ulcerative colitis and concomitant leukemia in our cohort of 1,111 IBD patients (838 with UC). Several types of leukemia have been so far reported in patients with ulcerative colitis including chronic myelocytic leukaemia, acute myelocytic leukaemia, acute lymphoblastic leukaemia and acute promyelocytic leukaemia [2] . In rare cases chronic myelocytic leukaemia in ulcerative colitis has been reported in combination with primary biliary cirrhosis [3] or psoriasis [4] .
The treatment of patients with chronic myelogenous leukemia continues to evolve rapidly as we gain better insight into the best monitoring strategies and as we gain experience with the second-generation tyrosine kinase inhibitors. Standard dose imatinib remains the best first-line therapy for most patients with first chronic phase myelogenous leukemia. Patient and disease-related factors have to be evaluated when considering alternatives such as higher doses of imatinib, dasatinib, nilotinib and allogeneic transplant. The course of bowel disease after allogeneic transplant seems to be quiescent in cases that have been so far reported [5] . To conclude, this is the first case of a patient with ulcerative colitis and leukemia in the northwest Greece IBD cohort.
